Update on RISUG

A much-anticipated update on the development of RISUG (reversible inhibition of sperm under guidance) was provided by journalist Sohini Chattopadhyay in a recent article in The Wire.  We haven’t heard much about the progress of clinical trials in the past few years, but the male contraceptive created in India by Prof. Sujoy Guha is reported to still be going through Phase III clinical trials there. Now 76 years of age, Prof. Guha is still waiting for his product to make it to market in India, a country that could benefit from new contraceptive options. The first paper on RISUG was published 37 years ago and the recent report outlines the ups and downs of the approval process in India. Parsemus Foundation has developed Vasalgel, which has a similar composition and application, and recognizes the important contributions of Prof. Guha to the field of male contraceptive research.

Tell us what you think

This form does not collect your email address. If you would like us to respond, please send questions to info@parsemus.org.
This field is for validation purposes and should be left unchanged.
We’re sorry, you are not eligible for the nationwide COVID-OUT or ACTIV-6 studies, but you may be eligible for other federal trials:

And if you don’t find a match there, this slightly more complex clinical trials finder includes studies sponsored by companies as well:

Trials Today